Revista nº 812

González Muñoz M, et al. | Efectividad terapias osteonecrosis de los maxilares Actual Med. 2021; 106(812): 66- 77 77 48. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg. 2011;69(9):2465-72. DOI: 10.1016/j. joms.2011.02.078 49. Bocanegra-Pérez S, Vicente-Barrero M, Knezevic M, Caste- llano-Navarro JM, Rodríguez-Bocanegra E, Rodríguez-Mi- llares J, et al. Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2012;41(11):1410-5. DOI: 10.1016/j. ijom.2012.04.020 50. Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-re- lated osteonecrosis of the jaw: a report of 32 cases. Oral Oncol. 2012;48(5):469-74. DOI: 10.1016/j.oraloncology.2011.12.004 51. Park JH, Kim JW, Kim SJ. Does the Addition of Bone Mor- phogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? J Oral Maxillofac Surg. 2017;75(6):1176-1184. DOI: 10.1016/j.joms.2016.12.005 52. Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 2011;47(5):420-4. DOI: 10.1016/j.oraloncology.2011.02.024 53. Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY. Short-term te- riparatide therapy as an adjunctive modality for bisphos- phonate-related osteonecrosis of the jaws. Osteoporos Int. 2012;23(11):2721-5. DOI: 10.1007/s00198-011-1882-9 54. Bodem JP, Kargus S, Engel M, Hoffmann J, Freudlsperger C. Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw. J Cra- niomaxillofac Surg. 2015;43(7):1139-43. DOI: 10.1016/j. jcms.2015.05.019 55. Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment? Oral Dis. 2018;24(1-2):238-242. DOI: 10.1111/odi.12764 56. Stübinger S, Dissmann JP, Pinho NC, Saldamli B, Seitz O, Sa- der R. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation. Lasers Surg Med. 2009;41(1):26-30. DOI: 10.1002/lsm.20730 57. Rugani P, Acham S, Truschnegg A, Obermayer-Pietsch B, Jakse N. Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case re- port. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(6):e1-6. DOI: 10.1016/j.tripleo.2010.08.013 58. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphona- tes. Laryngoscope. 2006;116(1):115-20. DOI: 10.1097/01. mlg.0000187398.51857.3c Los autores/as de este artículo declaran no tener nin- gún tipo de conflicto de intereses respecto a lo ex- puesto en el presente trabajo. CONFLICTO DE INTERESES Si desea citar nuestro artículo: González Muñoz M, Rodríguez-Archilla A. Efectividad de los distintos tratamientos de la osteonecrosis de los maxilares asociada a fármacos. Actual Med. 2021; 106(812): 66- 77. DOI: 10.15568/am.2021.812. rev02